Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)

Cathomas, Richard; Rothermundt, Christian; Klingbiel, Dirk; Bubendorf, Lukas; Jaggi, Rolf; Betticher, Daniel C; Brauchli, Peter; Cotting, Denise; Droege, Cornelia; Winterhalder, Ralph; Siciliano, Daniele; Berthold, Dominik R; Pless, Miklos; Schiess, Ralph; von Moos, Roger; Gillessen, Silke (2012). Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clinical cancer research, 18(21), pp. 6049-57. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-2219

Full text not available from this repository. (Request a copy)

The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pathologie > Forschungsgruppe Molekularbiologie

UniBE Contributor:

Jaggi, Rolf

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:37

Last Modified:

11 Jul 2018 17:14

Publisher DOI:

10.1158/1078-0432.CCR-12-2219

PubMed ID:

22977195

Web of Science ID:

000312020400024

URI:

https://boris.unibe.ch/id/eprint/15064 (FactScience: 222227)

Actions (login required)

Edit item Edit item
Provide Feedback